Amphipathic Peptide-Based Fusion Peptides and Immunoconjugates for the Targeted Ablation of Prostate Cancer Cells
Open Access
- 1 July 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (13) , 6368-6375
Abstract
We describe the design, generation, and in vitro evaluation of targeted amphipathic fusion peptides and immunoconjugates for the ablation of prostate cancer cells. The overexpression of the prostate-specific membrane antigen (PSMA) was exploited as means to specifically deliver cytotoxic peptides to prostate cancer cells. Cationic amphipathic lytic peptides were chosen as cytotoxic agents due to their ability to depolarize mitochondrial membranes and induce apoptosis. Specific delivery of the lytic peptide was facilitated by PSMA-targeting peptides and antibodies. Our results indicate that although the use of PSMA-targeted peptides only modestly enhanced the cytotoxic activity of the lytic peptide, peptide-antibody conjugates were two orders of magnitude more potent than untargeted peptide. In addition to quantifying the cytotoxic activities of the individual constructs, we also investigated the mechanisms of cell death induced by the fusion peptides and immunoconjugates. Although fusion peptides induced oncotic/necrotic death in cells, treatment with immunoconjugates resulted in apoptotic death. In summary, immunoconjugates based on lytic peptides are a promising class of therapeutics for prostate cancer therapy and warrant further investigation. [Cancer Res 2007;67(13):6368–75]Keywords
All Related Versions
This publication has 39 references indexed in Scilit:
- The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infectionNature Medicine, 2006
- Vaccination of hormone‐refractory prostate cancer patients with peptide cocktail‐loaded dendritic cells: Results of a phase I clinical trialThe Prostate, 2006
- Antibody-based therapeutics: Focus on prostate cancerCancer and Metastasis Reviews, 2005
- Selective Apoptotic Killing of Malignant Hemopoietic Cells by Antibody-Targeted Delivery of an Amphipathic PeptideCancer Research, 2005
- Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 HelixScience, 2004
- Therapeutic peptidesTrends in Biotechnology, 2003
- New Lytic Peptides Based on thed,l-Amphipathic Helix Motif Preferentially Kill Tumor Cells Compared to Normal CellsBiochemistry, 2003
- Peptides Targeting Caspase InhibitorsJournal of Biological Chemistry, 2003
- Pathological and molecular aspects of prostate cancerThe Lancet, 2003
- Mitochondrion as a Novel Target of Anticancer ChemotherapyJNCI: Journal of the National Cancer Institute, 2000